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Introduction
JIA related uveitis usually have an insidious onset and
chronic evolution. Some remain refractory to treatment
with classic immunomodulators and topical steroids, but
have been shown to respond to the addition of biological
agents (anti-tnfa). When to start biologicals, how to moni-
tor its ocular response and when and how to wean it,
remain a matter for debate. The SUN Working Group
scales of cell and flare grading remain the most commonly
used method of monitoring intra-ocular inflammation but
have clear limitations on the follow-up of chronic cases.
The measuring of anterior chamber flare with a Flaremeter
is more accurate but less frequently used.
Objectives
To report a case of refractory JIA uveitis treated with
infliximab, illustrating the importance of flare measure-
ments in the detection of incomplete response and in
infliximab dose optimization.
Methods
Restrospective review of a case file.
Results
BMF, female, caucasian, developed arthritis of the right
ankle at 3 years of age, followed 3 months later by
arthritis of the 3rd, 4th and 5th left hand proximal
interphalangeal joints and 4th right foot interphalangeal
joint. She was classified as an anti-nuclear antibodies
negative, rheumatoid factor negative polyarticular JIA,
responding well to non steroidal anti-inflammatories
and methotrexate (MTX) 10 mg/m2/wk, and achieving
complete remission after 6 months of treatment. At the
9th month after diagnosis, bilateral anterior uveitis was
diagnosed, thereafter recurring 3-4 times/year over the
next 4 years, despite increasing MTX to 15 mg/m2/wk.
Switching to cyclosporin added unnaceptable side effects
with no ocular improvement. At the 5th year after diag-
nosis (2009), she developed right knee arthritis and was
started on etanercept, with articular remission but no
ocular improvement. 6 months later, she was switched
to adalimumab, with no ocular benefit. After 4 months
(2010), she was switched to infliximab 4.4 mg/kg/6/6
weeks, developing uveitis remission. By then, best cor-
rected visual acuity (BCVA) remained 20/50 in each eye
due to cataracts, and there were multiple posterior syne-
cheae and band keratopathy. During the next 2 years no
anterior chamber cells were detected and flare remained
stable at 2+ in each eye, but BCVA gradually declined
until 20/200 due to worsening cataracts. A closer fol-
low-up with flaremeter measurements revealed a recur-
ring wave-like pattern of intraocular inflammation with
a minimum value of 538 phot/msec on the 2nd week of
infliximab and a maximal value on the sixth week of
615 phot/msec. A trial of topical prednisolone acetate
managed to further decrease the flare to a minimum of
490 phot/msec on the 2nd week of infliximab, confirming
inadequate intra-ocular inflammation control.
Conclusion
Current biomicroscopic standards of grading intra-ocular
inflammation are unsatisfactory for the follow-up of
chronic refractory anterior uveitis. In these specific cases,
mapping the intraocular inflammation with a more
objective tool seems advantageous, revealing variations of
intraocular inflammatory status otherwise undetected on
biomicroscopy. This may prove useful for both the
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